Real-World study tracks Ribociclib's impact on early breast cancer

NCT ID NCT06797531

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study follows 177 people with HR+/HER2- early breast cancer who are already taking ribociclib with hormone therapy as part of their routine care. Researchers will track how well the treatment works and any side effects over time. The goal is to see if the drug helps prevent cancer from coming back in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (a targeted cancer drug)
What this could lead to: If successful, this study could confirm that ribociclib combined with hormone therapy works well in real-world settings, potentially improving outcomes for people with HR+/HER2- early breast cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to a specific population in Saudi Arabia, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- EARLY BREAST CANCER

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Riyadh, 11211, Saudi Arabia
Novartis Investigative Site
RECRUITING

Riyadh, 11426, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.